The genetic basis of the fitness costs of antimicrobial resistance: A meta-analysis approach

Evolutionary Applications

Volumn 8, Issue 3, 2015, Pages 284-295

  Vogwill, Tom ^a   Maclean, R Craig ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Adaptation; Antibiotic resistance; Antimicrobial resistance; Fitness cost; Microbes; Mutation; Plasmid

Indexed keywords

EID: 84925296085     PISSN: 17524563     EISSN: 17524571     Source Type: Journal    
DOI: 10.1111/eva.12202     Document Type: Article

References (76)

1. Abdelraouf, K., S. Kabbara, K. R. Ledesma, K. Poole, and V. H. Tam 2011. Effect of multidrug resistance-conferring mutations on the fitness and virulence of Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy 66:1311-1317.
2. Adriaenssens, N., S. Coenen, A. Versporten, A. Muller, G. Minalu, C. Faes, V. Vankerckhoven et al. 2011. European Surveillance of Antimicrobial Consumption (ESAC): outpatient antibiotic use in Europe (1997-2009). Journal of Antimicrobial Chemotherapy 66:vi3-vi12.
3. Alekshun, M. N., and S. B. Levy 2007. Molecular mechanisms of antibacterial multidrug resistance. Cell 128:1037-1050.
4. Andersson, D. I. 2006. The biological cost of mutational antibiotic resistance: any practical conclusions? Current Opinion in Microbiology 9:461-465.
5. Andersson, D. I., and D. Hughes 2010. Antibiotic resistance and its cost: is it possible to reverse resistance? Nature Reviews Microbiology 8:260-271.
6. Andersson, D., H. Verseveld, A. Stouthamer, and C. Kurland 1986. Suboptimal growth with hyper-accurate ribosomes. Archives of Microbiology 144:96-101.
7. Austin, D. J., M. Kakehashi, and R. M. Anderson 1997. The transmission dynamics of antibiotic-resistant bacteria: the relationship between resistance in commensal organisms and antibiotic consumption. Proceedings of the Royal Society of London. Series B: Biological Sciences 264:1629-1638.
8. Austin, D. J., K. G. Kristinsson, and R. M. Anderson 1999. The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance. Proceedings of the National Academy of Sciences 96:1152-1156.
9. Baltrus, D. A. 2013. Exploring the costs of horizontal gene transfer. Trends in Ecology & Evolution 28:489-495.
10. Barlow, M. 2009, What antimicrobial resistance has taught us about horizontal gene transfer. In M. Gogarten, J. Gogarten, and L. Olendzenski, eds. Horizontal Gene Transfer, pp. 397-411. Humana Press, New York.
11. Binet, R., and A. T. Maurelli 2005. Fitness cost due to mutations in the 16S rRNA associated with spectinomycin resistance in Chlamydia psittaci 6BC. Antimicrobial Agents and Chemotheraphy 49:4455-4464.
12. Bonomo, R. A., and D. Szabo 2006. Mechanisms of multidrug resistance in Acenitobacter species and Pseudomonas aeruginosa. Clinical Infectious Disease 43:S49-S56.
13. Bouma, J. E., and R. E. Lenski 1988. Evolution of a bacteria/plasmid association. Nature 335:351-352.
14. Bruchmann, S., A. Dötsch, B. Nouri, I. F. Chaberny, and S. Häussler 2013. Quantitative contributions of target alteration and decreased drug accumulation to Pseudomonas aeruginosa fluoroquinolone resistance. Antimicrobial Agents and Chemotherapy 57:1361-1368.
15. Castaneda-Garcia, A., A. Rodriguez-Rojas, J. R. Guelfo, and J. Blazquez 2009. The glycerol-3-phosphate permease glpt is the only fosfomycin transporter in Pseudomonas aeruginosa. Journal of Bacteriology 191:6968-6974.
16. Corich, L., L. Dolzani, E. A. Tonin, L. A. Vitali, and C. Lagatolla 2010. Metallo-beta-lactamase expression confers an advantage to Pseudomonas aeruginosa isolates compared with other beta-lactam resistance mechanisms, favoring the prevalence of metallo-beta-lactamase producers in a clinical environment. Microbial Drug Resistance 16:223-230.
17. Dahlberg, C., and L. Chao 2003. Amelioration of the cost of conjugative plasmid carriage in Eschericha coli K12. Genetics 165:1641-1649.
18. Dionisio, F., I. C. Conceição, A. C. R. Marques, L. Fernandes, and I. Gordo 2005. The evolution of a conjugative plasmid and its ability to increase bacterial fitness. Biology Letters 1:250-252.
19. Enne, V. I., A. A. Delsol, G. R. Davis, S. L. Hayward, J. M. Roe, and P. M. Bennett 2005. Assessment of the fitness impacts on Escherichia coli of acquisition of antibiotic resistance genes encoded by different types of genetic element. Journal of Antimicrobial Chemotherapy 56:544-551.
20. Farhat, M. R., B. J. Shapiro, K. J. Kieser, R. Sultana, K. R. Jacobson, T. C. Victor, R. M. Warren et al. 2013. Genomic analysis identifies targets of convergent positive selection in drug-resistant Mycobacterium tuberculosis. Nature Genetics 45:1183-1189.
21. Foucault, M.-L., P. Courvalin, and C. Grillot-Courvalin 2009. Fitness cost of vana-type vancomycin resistance in methicillin-resistant Staphylococcus aureus. Antimicrobial Agents and Chemotheraphy 53:2354-2359.
22. Foucault, M.-L., F. Depardieu, P. Courvalin, and C. Grillot-Courvalin 2010. Inducible expression eliminates the fitness cost of vancomycin resistance in enterococci. Proceedings of the National Academy of Sciences 107:16964-16969.
23. Goossens, H., M. Ferech, S. Coenen, and P. Stephens, Group E.S.o.A.C.P. 2007, Comparison of outpatient systemic antibacterial use in 2004 in the United States and 27 European countries. Clinical Infectious Diseases 44, 1091-1095.
24. Guo, B. N., K. Abdelraouf, K. R. Ledesma, M. Nikolaou, and V. H. Tam 2012. Predicting bacterial fitness cost associated with drug resistance. Journal of Antimicrobial Chemotherapy 67:928-932.
25. Gurevitch, J., and L. V. Hedges 1999. Statistical issues in ecological meta-analyses. Ecology 80:1142-1149.
26. Gurevitch, J., P. S. Curtis, and M. H. Jones 2001. Meta-analysis in ecology. Advances in Ecological Research 32:199-247.
27. Gustafsson, I., O. Cars, and D. I. Andersson 2003. Fitness of antibiotic resistant Staphylococcus epidermidis assessed by competition on the skin of human volunteers. Journal of Antimicrobial Chemotherapy 52:258-263.
28. Hall, A. R., and R. C. MacLean 2011. epistasis buffers the fitness effects of rifampicin- resistance mutations in Pseudomonas aeruginosa. Evolution 65:2370-2379.
29. Hedges, L. V., J. Gurevitch, and P. S. Curtis 1999. The meta-analysis of response ratios in experimental ecology. Ecology 80:1150-1156.
30. Hughes, V. M., and N. Datta 1983. Conjugative plasmids in bacteria of the /'pre-antibiotic/' era. Nature 302:725-726.
31. Jalal, S., O. Ciofu, N. Høiby, N. Gotoh, and B. Wretlind 2000. Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrobial Agents and Chemotheraphy 44:710-712.
32. Knight, G. M., E. L. Budd, and J. A. Lindsay 2013. Large mobile genetic elements carrying resistance genes that do not confer a fitness burden in healthcare-associated meticillin-resistant Staphylococcus aureus. Microbiology 159:1661-1672.
33. Kunz, A. N., A. A. Begum, H. Wu, J. A. D'Ambrozio, J. M. Robinson, W. M. Shafer, M. C. Bash et al. 2012. Impact of fluoroquinolone resistance mutations on gonococcal fitness and in vivo selection for compensatory mutations. Journal of Infectious Diseases, 205:1821-1829.
34. Kusuma, C., A. Jadanova, T. Chanturiya, and J. F. Kokai-Kun 2007. Lysostaphin-resistant variants of staphylococcus aureus demonstrate reduced fitness in vitro and in vivo. Antimicrobial Agents and Chemotheraphy 51:475-482.
35. Levy, S. B., and B. Marshall 2004. Antibacterial resistance worldwide: causes, challenges and responses. Nature Medicine, 10:S122-S129.
36. Lindgren, P. K., L. L. Marcusson, D. Sandvang, N. Frimodt-Møller, and D. Hughes 2005. Biological cost of single and multiple norfloxacin resistance mutations in Escherichia coli implicated in urinary tract infections. Antimicrobial Agents and Chemotheraphy 49:2343-2351.
37. Lipsitch, M., C. T. Bergstrom, and B. R. Levin 2000. The epidemiology of antibiotic resistance in hospitals: paradoxes and prescriptions. Proceedings of the National Academy of Sciences 97:1938-1943.
38. Lister, P. D., D. J. Wolter, and N. D. Hanson 2009. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clinical Microbiology Reviews 22:582-610.
39. Livermore, D. M. 2002. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clinical Infectious Diseases 34:634-640.
40. MacLean, R. C., A. R. Hall, G. G. Perron, and A. Buckling 2010. The population genetics of antibiotic resistance: integrating molecular mechanisms and treatment contexts. Nature Reviews Genetics 11:405-414.
41. Macvanin, M., U. Johanson, M. Ehrenberg, and D. Hughes 2000. Fusidic acid-resistant EF-G perturbs the accumulation of ppGpp. Molecular Microbiology 37:98-107.
42. Marciano, D. C., O. Y. Karkouti, and T. Palzkill 2007. A fitness cost associated with the antibiotic resistance enzyme SME-1 beta-lactamase. Genetics 176:2381-2392.
43. Marcusson, L. L., N. Frimodt-Møller, and D. Hughes 2009. Interplay in the selection of fluoroquinolone resistance and bacterial fitness. PLoS Pathogens 5:e1000541.
44. Martinez, J. L., F. Baquero, and D. I. Andersson 2007. Predicting antibiotic resistance. Nature Reviews Microbiology 5:958-965.
45. Mc Ginty, S. É., and D. J. Rankin 2012. The evolution of conflict resolution between plasmids and their bacterial hosts. Evolution 66:1662-1670.
46. Mc Ginty, S. E., D. J. Rankin, and S. P. Brown 2011. Horizontal gene transfer and the evolution of bacterial cooperation. Evolution 65:21-32.
47. Moya, B., C. Juan, S. Albertí, J. L. Pérez, and A. Oliver 2008. Benefit of having multiple ampd genes for acquiring β-lactam resistance without losing fitness and virulence in pseudomonas aeruginosa. Antimicrobial Agents and Chemotheraphy 52:3694-3700.
48. Muller, B., S. Borrell, G. Rose, and S. Gagneux 2013. The heterogeneous evolution of multidrug-resistant Mycobacterium tuberculosis. Trends in Genetics 29:160-169.
49. Nogueira, T., D. J. Rankin, M. Touchon, F. Taddei, S. P. Brown, and E. P. C. Rocha 2009. Horizontal gene transfer of the secretome drives the evolution of bacterial cooperation and virulence. Current Biology 19:1683-1691.
50. Norström, T., J. Lannergård, and D. Hughes 2007. Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus. Antimicrobial Agents and Chemotheraphy 51:4438-4446.
51. Olivares, J., C. Alvarez-Ortega, J. F. Linares, F. Rojo, T. Köhler, and J. L. Martínez 2012. Overproduction of the multidrug efflux pump MexEF-OprN does not impair Pseudomonas aeruginosa fitness in competition tests, but produces specific changes in bacterial regulatory networks. Environmental Microbiology 14:1968-1981.
52. Paulander, W., A. Pennhag, D. I. Andersson, and S. Maisnier-Patin 2007. Caenorhabditis elegans as a model to determine fitness of antibiotic-resistant Salmonella enterica serovar typhimurium. Antimicrobial Agents and Chemotheraphy 51:766-769.
53. Paulander, W., S. Maisnier-Patin, and D. I. Andersson 2009. The fitness cost of streptomycin resistance depends on rpsl mutation, carbon source and RpoS (σS). Genetics 183:539-546.
54. Pränting, M., and D. I. Andersson 2011. Escape from growth restriction in small colony variants of Salmonella typhimurium by gene amplification and mutation. Molecular Microbiology 79:305-315.
55. Pränting, M., A. Negrea, M. Rhen, and D. I. Andersson 2008. Mechanism and fitness costs of PR-39 resistance in Salmonella enterica serovar typhimurium LT2. Antimicrobial Agents and Chemotheraphy 52:2734-2741.
56. Rankin, D. J., E. P. C. Rocha, and S. P. Brown 2011. What traits are carried on mobile genetic elements, and why[quest]. Heredity 106:1-10.
57. San Millan, A., J. A. Escudero, B. Gutierrez, L. Hidalgo, N. Garcia, M. Llagostera, L. Dominguez et al. 2009. Multiresistance in Pasteurella multocida is mediated by coexistence of small plasmids. Antimicrobial Agents and Chemotheraphy 53:3399-3404.
58. Sandegren, L., A. Lindqvist, G. Kahlmeter, and D. I. Andersson 2008. Nitrofurantoin resistance mechanism and fitness cost in Escherichia coli. Journal of Antimicrobial Chemotherapy 62:495-503.
59. Sandegren, L., M. Linkevicius, B. Lytsy, A. Melhus, and D. I. Andersson 2012. Transfer of an Escherichia coli ST131 multiresistance cassette has created a Klebsiella pneumoniae-specific plasmid associated with a major nosocomial outbreak. Journal of Antimicrobial Chemotherapy 67:74-83.
60. Sandgren, A., M. Strong, P. Muthukrishnan, B. K. Weiner, G. M. Church, and M. B. Murray 2009. Tuberculosis drug resistance mutation database. PLoS Medicine 6:e1000002.
61. Schrag, S. J., and V. Perrot 1996. Reducing antibiotic resistance. Nature 381:120-121.
62. Seaman, P. F., D. Ochs, and M. J. Day 2007. Small-colony variants: a novel mechanism for triclosan resistance in methicillin-resistant Staphylococcus aureus. Journal of Antimicrobial Chemotherapy 59:43-50.
63. Somoskovi, A., L. Parsons, and M. Salfinger 2001. The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis. Respiratory Research 2:164-168.
64. Starikova, I., K. Harms, P. Haugen, T. T. M. Lunde, R. Primicerio, Ø. Samuelsen, K. M. Nielsen et al. 2012. A trade-off between the fitness cost of functional integrases and long-term stability of integrons. PLoS Pathogens 8:e1003043.
65. Starikova, I., M. Al-Haroni, G. Werner, A. P. Roberts, V. Sørum, K. M. Nielsen, and P. J. Johnsen 2013. Fitness costs of various mobile genetic elements in Enterococcus faecium and Enterococcus faecalis. Journal of Antimicrobial Chemotherapy 68:2755-2765.
66. Trindade, S., A. Sousa, K. B. Xavier, F. Dionisio, M. G. Ferreira, and I. Gordo 2009. Positive epistasis drives the acquisition of multidrug resistance. PLoS Genetics 5:e1000578.
67. de Visser, J. A. G. M., T. F. Cooper, and S. F. Elena 2011. The causes of epistasis. Proceedings of the Royal Society B: Biological Sciences 278:3617-3624.
68. Wang, H., J. L. Dzink-Fox, M. Chen, and S. B. Levy 2001. Genetic characterization of highly fluoroquinolone-resistant clinical Escherichia coli strains from China: role ofacrR mutations. Antimicrobial Agents and Chemotheraphy 45:1515-1521.
69. Ward, H., G. G. Perron, and R. C. Maclean 2009. The cost of multiple drug resistance in Pseudomonas aeruginosa. Journal of Evolutionary Biology 22:997-1003.
70. Wehrli, W. 1983. Rifampin: mechanisms of action and resistance. Reviews of Infectious Diseases 5:S407-S411.
71. Weigel, L. M., G. J. Anderson, R. R. Facklam, and F. C. Tenover 2001. Genetic analyses of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae. Antimicrobial Agents and Chemotheraphy 45:3517-3523.
72. Weinreich, D. M., N. F. Delaney, M. A. DePristo, and D. L. Hartl 2006. Darwinian evolution can follow only very few mutational paths to fitter proteins. Science 312:111-114.
73. zur Wiesch, P. A., R. Kouyos, J. Engelstädter, R. R. Regoes, and S. Bonhoeffer 2011. Population biological principles of drug-resistance evolution in infectious diseases. The Lancet Infectious Diseases 11:236-247.
74. Zhang, H., D. Li, L. Zhao, J. Fleming, N. Lin, T. Wang, Z. Liu et al. 2013. Genome sequencing of 161 Mycobacterium tuberculosis isolates from China identifies genes and intergenic regions associated with drug resistance. Nature Genetics 45:1255-1260.
75. Zorzet, A., M. Y. Pavlov, A. I. Nilsson, M. Ehrenberg, and D. I. Andersson 2010. Error-prone initiation factor 2 mutations reduce the fitness cost of antibiotic resistance. Molecular Microbiology 75:1299-1313.
76. Zorzet, A., J. M. Andersen, A. I. Nilsson, N. F. Møller, and D. I. Andersson 2012. Compensatory mutations in agrC partly restore fitness in vitro to peptide deformylase inhibitor-resistant Staphylococcus aureus. Journal of Antimicrobial Chemotherapy 67:1835-1842.